NewAmsterdam Pharma Company N.V. (NAMSW) 是一家上市公司 屬於 醫療保健 板塊，經營於 生物科技 產業. 公司總部位於 Naarden, 荷兰. 現任CEO為 Michael Harvey Davidson Facp..
NAMSW 擁有 IPO日期為 2021-02-10, 68 名全職員工, 在 NASDAQ Capital Marke, 市值為 $2.69B.
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.
